Phase II trial of monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor (GM-CSF) for neuroblastoma
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2013
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Sargramostim (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 22 Dec 2009 Actual end date (April 2005) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2005 New trial record.